T. Rowe Price Associates
ANAB icon

T. Rowe Price Associates’s AnaptysBio ANAB Stock Holding History

T. Rowe Price Associates’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
32,374
+2,683
+9% +$163K ﹤0.01% 1960
2026
Q1 		$1.65M Buy
29,691
+3,686
+14% +$198K ﹤0.01% 1916
2025
Q4 		$1.26M Sell
26,005
-273,306
-91% -$10.7M ﹤0.01% 1978
2025
Q3 		$9.17M Sell
299,311
-373,860
-56% -$8.58M ﹤0.01% 1246
2025
Q2 		$14.9M Sell
673,171
-241,910
-26% -$5.06M ﹤0.01% 1028
2025
Q1 		$17M Sell
915,081
-9,926
-1% -$166K ﹤0.01% 992
2024
Q4 		$12.2M Buy
925,007
+1,890
+0.2% +$45.8K ﹤0.01% 1111
2024
Q3 		$30.9M Buy
923,117
+622,893
+207% +$21.3M ﹤0.01% 884
2024
Q2 		$7.53M Buy
300,224
+128,535
+75% +$2.99M ﹤0.01% 1150
2024
Q1 		$3.87M Sell
171,689
-60,065
-26% -$1.42M ﹤0.01% 1298
2023
Q4 		$4.96M Buy
231,754
+5,472
+2% +$94.4K ﹤0.01% 1210
2023
Q3 		$4.07M Buy
+226,282
New +$4.32M ﹤0.01% 1220
2023
Q1 		– Sell
-12,579
Closed -$390K – 2925
2022
Q4 		$390K Buy
12,579
+320
+3% +$9.04K ﹤0.01% 2259
2022
Q3 		$313K Buy
12,259
+1,276
+12% +$29.9K ﹤0.01% 2358
2022
Q2 		$223K Buy
10,983
+111
+1% +$2.46K ﹤0.01% 2555
2022
Q1 		$269K Buy
10,872
+475
+5% +$14.4K ﹤0.01% 2591
2021
Q4 		$361K Buy
10,397
+2,257
+28% +$71.6K ﹤0.01% 2528
2021
Q3 		$221K Sell
8,140
-126
-2% -$3.2K ﹤0.01% 2686
2021
Q2 		$214K Sell
8,266
-1,514
-15% -$36.3K ﹤0.01% 2705
2021
Q1 		$211K Sell
9,780
-323,124
-97% -$8.16M ﹤0.01% 2672
2020
Q4 		$7.16M Buy
+332,904
New +$8.08M ﹤0.01% 1393
2019
Q4 		– Sell
-864,204
Closed -$30.2M – 2529
2019
Q3 		$30.2M Sell
864,204
-73,069
-8% -$3.48M ﹤0.01% 1030
2019
Q2 		$52.9M Buy
937,273
+147,292
+19% +$10.6M 0.01% 868
2019
Q1 		$57.7M Buy
789,981
+364,593
+86% +$25.2M 0.01% 819
2018
Q4 		$27.1M Buy
425,388
+38,919
+10% +$2.89M ﹤0.01% 1049
2018
Q3 		$38.6M Sell
386,469
-48,759
-11% -$4.05M 0.01% 1011
2018
Q2 		$30.9M Buy
435,228
+233,748
+116% +$19.6M ﹤0.01% 1060
2018
Q1 		$21M Buy
201,480
+92,383
+85% +$10.4M ﹤0.01% 1166
2017
Q4 		$11M Buy
+109,097
New +$8.03M ﹤0.01% 1324

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

T. Rowe Price Associates's ANAB Position: Q2 2026 in Review

T. Rowe Price Associates increased its AnaptysBio (ANAB) stake by 9% in Q2 2026, buying an estimated $163K and bringing the position to 32,374 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1960.

T. Rowe Price Associates first reported a position in ANAB in Q4 2017 and has held it in 29 quarters since. The position peaked at $57.7M in Q1 2019. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • T. Rowe Price Associates held 32,374 shares of AnaptysBio worth $2.19M as of Q2 2026.
  • T. Rowe Price Associates bought 2,683 AnaptysBio shares in Q2 2026, an estimated $163K.
  • AnaptysBio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1960 holding.
  • T. Rowe Price Associates first reported a position in AnaptysBio in Q4 2017 and has held it in 29 quarters since.
  • T. Rowe Price Associates's AnaptysBio position peaked at $57.7M in Q1 2019.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.